2+ mishandling is an underlying mechanism in hypoxia/reoxygenation (H/R) injury that results in mitochondrial dysfunction and cardiomyocytes death. These events are mediated by mitochondrial Ca 2+ (mCa 2+ ) overload that is facilitated by the mitochondrial calcium uniporter (MCU) channel. Along this line, we evaluated the effect of siRNA-targeting MCU in cardiomyocytes subjected to H/R injury. First, cardiomyocytes treated with siRNA demonstrated a reduction of MCU expression by 67%, which resulted in significant decrease in mitochondrial Ca 2+ transport. siRNA treated cardiomyocytes showed decreased mitochondrial permeability pore opening and oxidative stress trigger by Ca 2+ overload. Furthermore, after H/R injury MCU silencing decreased necrosis and apoptosis levels by 30% and 50%, respectively, and resulted in reduction in caspases 3/7, 9, and 8 activity. Our findings are consistent with previous conclusions that demonstrate that MCU activity is partly responsible for cellular injury induced by H/R and support the concept of utilizing siRNA-targeting MCU as a potential therapeutic strategy.
Introduction
Coronary heart disease (CHD) is the leading cause of death in industrialized and third-world countries [1] . The effects of CHD are associated with the negative effects of ischemiareperfusion. Ischemia-reperfusion injury normally arises in patients presenting myocardial infarction with acute STsegment elevation in which timely and effective myocardial reperfusion is limiting the infarct size and death. However, several events that appear during myocardial reperfusion can induce further cell damage in a phenomenon known as reperfusion injury [2] .
Numerous experimental studies have identified some critical factors that act in concert to mediate the unfavorable effects of reperfusion injury. First, intracellular and mitochondrial Ca 2+ (mCa 2+ ) overload are exacerbated during reperfusion due to oxidative stress-induced disruption of the sarcolemma and sarcoplasmic reticulum membranes [3] . Second, mitochondrial reenergization during reoxygenation allows the recovery of the membrane potential that drives the Ca 2+ uptake into the mitochondria through the mitochondrial Ca 2+ uniporter (MCU) channel and subsequently induces mCa 2+ overload [4] . These events result in mitochondrial dysfunction, leading to cardiomyocyte death by the opening of the mitochondrial transition pore ( PTP) [5] . Accordingly, targeting oxidative stress and/or modulating the activity of MCU by a selective blocker such as Ru 360 [6, 7] or the inhibition of PTP opening by cyclosporine A (CsA) provide specific targets for intervention [8] .
The role of MCU in the regulation of mCa 2+ overload is supported by the observations that, in a model of cardiac 2 Oxidative Medicine and Cellular Longevity ischemia-reperfusion, treatment with Ru 360 decreased the [Ca 2+ ] and maintained mitochondrial ATP synthesis [6] . Ru 360 -treated hearts following in vivo reperfusion were less prone to undergo mitochondrial permeability transition ( PTP) and apoptosis [9, 10] . The recent description of the molecular identity of the MCU channel [11, 12] and several subunits that are crucial for mCa 2+ uptake allowed for the development of adult heart-specific transgenic models [13] . In this regard, conditional cardiac-specific MCU −/− mice subjected to reperfusion resulted in significant reduction of mCa 2+ overload that disabled the activation of PTP and inhibited cardiomyocytes apoptosis and necrosis [14, 15] . These data together provide experimental rationale to develop strategies to target MCU activity with the purpose of preventing ischemic-reoxygenation injury.
On the other hand, small interfering RNA-(siRNA-) based treatments provide a potential therapeutic strategy to block MCU activity. Of interest, several phases I and II clinical studies involving patients with hepatitis, hypercholesterolemia, macular degeneration, and solid tumors have been completed [16] and appear to be safe strategy for gene therapy in humans [17] .
Therefore, the purpose of this study was to explore the potential use of siRNA-targeting MCU in an in vitro model of hypoxia/reoxygenation (H/R) injury. Our results confirm previous observations that define the MCU as an essential modulator of the detrimental effects of reperfusion injury and suggest that MCU silencing using siRNA has the therapeutic potential to be used as a cardioprotective strategy.
Materials and Methods

Reagents.
All chemical reagents, cell culture media and supplements, siRNA, and fluorescent probes were purchased from Sigma-Aldrich (St. Louis, MO, USA), unless otherwise stated.
MCU siRNA Sequence.
To silence MCU, specific siRNA sequence was designed using RNAi siDirect v2.0 with the lowest predicted off-target potentials and 100% homology with the rat gene (NCBI Reference Sequence NM 001106398.1). Then, we used siRNA-MCU Calcium1, nt 761-779 of the corresponding mRNA, sense strand sequence: 5 -CGGCUUACCUGGUGGGAAU-3 . siRNA duplex was synthesized by Sigma-Aldrich (St. Louis, MO, USA). The nontargeting siRNA sequence is the MISSION5 siRNA Universal Negative Control #1 (SIC001) named as siRNA-Neg. 
Cell
Measurements of ROS Production.
To assess mitochondrial ROS (superoxide) production, transfected cardiomyocytes were stained with MitoSOX Red (Thermo Fisher Scientific), as previously reported by Mukhopadhyay et al. [20] . Briefly, cells were allowed to load MitoSOX for 30 min at 37 ∘ C. After staining, the cells were washed with Tyrode solution. Finally, each sample was stimulated with TG at a concentration of 5 M. Before TG addition, siRNA-Neg cardiomyocytes were incubated with or without 5 M Ru 360 for 30 min or 1 M CsA during 10 min as pharmacological inhibitors of superoxide production. Serial analysis of the samples was performed at different time points (0.5, 15, 30, 60, and 120 min). The data of the MitoSOX are presented as the fold increase of median intensity fluorescence against the siRNA-Neg controls.
Cytotoxicity Assay.
Cell viability and apoptotic and necrotic cell death were measured by Annexin V/PI staining followed by flow cytometry analysis. Briefly, after normoxy (Nxy), hypoxia, and 1.5 and 3 h reoxygenation conditions, H9c2 transfected cells were washed, resuspended in 195 L Tyrode + 2.5 mM CaCl 2 solution, and stained with 5 L of Annexin V Apoptosis Detection Set PE-Cy7 88-8103 (eBioscience, San Diego, CA, USA) for 10 min. Later, cells were washed and resuspended in 195 L Tyrode + 2.5 mM CaCl 2 solution and incubated with 100 ng of PI (P4170) to discard necrotic cells. Stained cells were immediately analyzed by flow cytometry. The assay was performed with a two-coloranalysis of PE-Cy7-labeled Annexin V binding and PI dye excited with 488 nm laser. To evaluate the proportions of viable, apoptotic, and necrotic cells, we performed fluorescence compensation. After discarding doublets, the living , and 20 Na + -lactate, pH 6.8) [21] and transferred into an anaerobic chamber with an oxygen level <1% at 37 ∘ C. After 3 h hypoxia, cells were washed and incubated with Tyrode (plus 5 mM glucose, 1.8 mM CaCl 2 ) and transferred into an incubator in normoxic conditions (37 ∘ C with 5% CO 2 and 95% air) for 1.5 and 3 h for reoxygenation and analyzed for apoptosis and necrosis at each time. During hypoxia, an experimental group remained in normoxic conditions. A schematic representation of hypoxia/reoxygenation model is shown in Figure 1 .
Caspase Activity Measurements.
For caspase activity measurements, H9c2 were seeded at 1.5 × 10 3 cells per well in 96-well plates and 24 h later were transfected as described previously. After 96 h of transfection, the cells were washed with Tyrode, incubated with IT solution, and transferred into an anaerobic chamber with an oxygen level <1% at 37 ∘ C. After 3 h hypoxia, IT solution was removed and cells were incubated with DMEM at normoxic conditions (37 ∘ C with 5% CO 2 and 95% air) for 0, 1.5, and 3 h reoxygenation and analyzed for caspases 3 and 7 and caspases 8 and 9 activity at each time. During hypoxia, an experimental group remained in normoxic conditions. The activity of caspases 3 and 7 and caspase 9 and caspase 8 was measured using Caspase-Glo 3/7, At normoxic conditions, siRNA-Neg (control group) and siRNA-MCU cardiomyocytes were subjected to 3 h of normothermic hypoxia (H) with an ischemic Tyrode solution (IT) followed by 3 h of reoxygenation (R). Transfected cardiomyocytes were harvested when indicated by arrows: measurements of necrosis and apoptosis by flow cytometry were performed and caspases 3 and 7 and caspases 9 and 8 activity were determined as described in Materials and Methods. Nxy, normoxy.
9, and 8 assay (Promega, Madison, WI, USA), respectively, according to the manufacturer's protocols. 
Results
siRNA-Targeting MCU Efficiently Decreases Mitochondrial Ca 2+ Transport in Cardiomyocytes.
Rat cardiomyocytes were transfected with specific MCU-targeted siRNA (siRNA-MCU) or nonsilencing siRNA (siRNA-Neg) to investigate the role of MCU in cell death. Using qPCR assays, we determined that there was a 70% ± 5 ( < 0.001) reduction in MCU mRNA expression levels up to 96 h after transfection (Figure 2(a) ). Next, our silencing effects were verified using western blot assays. In cardiomyocytes transfected with the siRNA-MCU, MCU expression was lower than that in those transfected with siRNA-Neg cells. This effect showed a timedependent response with a ∼50% silencing at 48 and 72 h (Figure 2(b) ). Moreover, at 96 h of transfection, we found significantly lower MCU protein levels by 67% ± 8 ( < 0.001). In addition, under this condition the concentration of MCU siRNAs used (225 nM) did not adversely affect the number of viable cells or the cardiomyocyte morphology and ATP production (Suppl. Figure 1A -E, Supplementary Material available online at https://doi.org/10.1155/2017/5750897). Based on these results, we used siRNAs at 225 nM for 96 hrs in the remainder of our experiments, in which we obtained the maximal silencing of MCU mRNA and protein expression (Figures 3(a) and 3(b) ). In addition, siRNA-MCU did not modify the relative expression of other uniplex components, such as MICU1, MICU2, EMRE, and MCUR1 (Figure 2(c) ).
Figure 3(c) shows representative mCa 2+ uptake traces for the control and MCU-silenced cardiomyocytes. Permeabilized transfected cardiomyocytes were challenged with a 15 M Ca 2+ addition in the presence of 1 M CsA to determine the maximum MCU activity [9] . In control cells, a rapid mCa 2+ entry was observed (completely abolished by Ru 360, data not shown); however, in siRNA-MCU treated cells, the Ca 2+ transport was drastically reduced. Mitochondrial Ca
2+
uptake time to its 50% (T 50% ) provides a quantitative index of MCU activity. For the control cardiomyocytes, T 50% was 1.08 ± 0.22 min, while, in MCU-silenced cells, it was 2.02 ± 0.4 min ( < 0.05) (Figure 3(d) ). These results indicate a significant reduction in the rate of mitochondrial transport in our MCU-silenced cardiomyocytes. Figure 1C-D) . Nevertheless, after a Ca 2+ pulse, the control cardiomyocytes showed a significant Ca 2+ -dependent depolarization compared with MCU-silenced cardiomyocytes (Figure 4(a) ). At the same time, MCU-silenced cells were able to maintain Δ in ∼ 75% ( < 0.05) (Figure 4(b) ). Ru 360 and CsA treatment protected against Ca 2+ -induced membrane depolarization by ∼95% (Figures 4(c) and 4(d) and Suppl. Figure 2A) .
MCU Silencing Reduces Mitochondrial
Moreover, in Ca 2+ retention experiments with a 50 M Ca 2+ bolus, we observed an early and dramatic release of Ca 2+ from control cardiomyocytes compared with the MCUsilenced cells (Suppl. Figure 2B ). Ca by CsA, indicating the involvement of PTP as a trigger of membrane potential collapse.
Oxidative stress and Ca 2+ overload are known to have detrimental effects on mitochondrial membrane integrity since both are inducers of PTP opening [22] . Figure 5(a) shows the time-course analysis of superoxide production in response to TG-induced Ca 2+ overload. At basal conditions, the control and MCU-silenced cardiomyocytes showed a similar fluorescence intensity of MitoSOX. After 60 and 120 min of TG treatment, MitoSOX intensity was significantly higher in siRNA-Neg transfected cells than in MCU-deficient cardiomyocytes ( Figure 5(a) ). Therefore, MCU-deficient cardiomyocytes showed a 51% ( < 0.001) reduction in Ca 2+ overload-induced superoxide production ( Figure 5(b) ). Under these conditions, the Ru 360 and CsA treatment also decreases ROS production by 22% (ns) and 49% ( < 0.001), respectively ( Figure 5(c) ). In accordance with these findings, MCU silencing might exert protective effects by reducing oxidative stress induced by Ca 2+ overload.
MCU Silencing Reduces Cardiomyocyte Cell Death in
Hypoxia/Reoxygenation Injury. Transfected cardiomyocytes were incubated for 3 h in a hypoxic chamber for O 2 (1%) in combination with glucose-deprivation, serum-free, and acidosis (pH 6.8) conditions to induce hypoxia. A schematic model of hypoxia/reoxygenation is shown in Figure 1 . Cell viability and apoptosis were determined by Annexin V/PI staining and analyzed by flow cytometry at specific time points during Nxy and during reoxygenation: at the beginning (0 h), after 1. ∼90% (Suppl. Figure 1A) and apoptosis was ∼3-5% in both transfected cardiomyocytes at normoxic conditions. At the onset of reoxygenation, we did not find any changes in cell death between the controls (12.6%) and the MCU-silenced cardiomyocytes (8.2%), as shown in Figure 6 (c). However, after 1.5 h of reoxygenation, necrosis increased by 46% in the control cardiomyocytes compared to the MCU-silenced cardiomyocytes (16.7%, < 0.05). After 3 h of reoxygenation, the viable cells were preserved in MCU-silenced cardiomyocytes in 60.3 ± 8% and then dropped by 30.5 ± 3.6% ( < 0.01) in the control cardiomyocytes. Apoptotic cell death measurements showed similar results; no significant changes were observed in the level of apoptosis at Nxy or the beginning of reoxygenation between the experimental groups. Nevertheless, we found a twofold decrease in MCUdeficient (4.3 ± 1.1) versus siRNA-Neg cardiomyocytes (8.4 ± 0.67) after 1.5 h of reoxygenation ( < 0.01). In the same way, after 3 h of reoxygenation, the apoptosis level increased 1.5-fold in siRNA-Neg cardiomyocytes (9.12 ± 0.94 versus 6.04 ± 0.5, < 0.05). Accordingly, caspases 3 and 7 activities increased by 2-fold at the onset of reoxygenation in the control cardiomyocytes (6.86 ± 0.18) compared to the MCU-deficient cardiomyocytes (3.38 ± 0.7, < 0.001). At the same time, caspase 9 activity increased significantly ( < 0.001) in both experimental groups, but, after 1.5 h of reoxygenation, the activation levels of caspase 9 dropped 1.5-fold in the MCU-deficient cardiomyocytes ( < 0.01). In fact, the activation of caspase 9 and caspases 3 and 7 persisted until 3 h after reoxygenation in siRNANeg cells compared to the MCU-silenced cardiomyocytes. Additionally, we observed an 18-fold increase in activation of caspase 8 at the onset of reoxygenation in control cells. Nevertheless, we observed a 40% reduction in caspase 8 activity in MCU-silenced cells compared with control cells reduces necrosis and apoptosis of the hypoxia/reoxygenation injury.
Discussion
In the heart, mCa 2+ uptake can shape cytosolic calcium signals to regulate some physiological processes, principally matching workload and energy production [23] . Nevertheless, an excessive uptake of Ca 2+ triggers mitochondrial dysfunction through PTP opening, leading to cell injury by apoptosis and necrosis [5] . In this regard, several studies have suggested that dysregulation of cytosolic Ca 2+ which leads to mCa 2+ overload is present in the physiopathology of ischemia/reperfusion (I/R) injury and heart failure (HF) [24] . The MCU channel, the principal mCa 2+ transport system, carries out this mechanism. However, the precise role in the regulation of Ca 2+ handling and its consequences on heart disease remain controversial [25] . Not until recently has the molecular characterization of the MCU been made possible [11, 12] , allowing for the study of its univocal role in the physiopathology of myocardial diseases. This finding led us to explore the possibility of modulating MCU expression in knockout mice or using a siRNA technology. In this regard, we tested a specific siRNA design to knock down MCU expression in the cardiomyocyte line for an in vitro MCU target validation. After being challenged to a mCa 2+ overload, MCU-deficient cells were able to largely sustain Δ and retain Ca 2+ similarly to those pharmacologically treated with CsA, as expected. Altogether, these findings indicate that MCU silencing confers resistance to PTP opening [6, 14] . Furthermore, MCU-silenced cardiomyocytes treated with TG (a SR-Ca 2+ /ATPase (SERCA) inhibitor), which promotes a burst of cytosolic Ca superoxide radical production. Also, after H/R protocol, siRNA-MCU-silenced cardiomyocytes reduced PTP opening and activation of caspases 8 and 9. In accordance with our results, caspase 8 might initiate the execution phase of cell apoptosis, after which mitochondrial dysfunction induces activation of caspase 9. One potential explanation for this finding is that caspase 8 activation cleaves Bid [26] , and then the cleaved Bid activates mitochondrial Bax/Bak and contributes to multiple mitochondrial dysfunction, including the release of the intramembrane space proteins, and activation of apaf-1, which in turn cleaves the proenzyme of caspase 9 into the active form. These observations are similar to those reported when Ru 360 -MCU was inhibited in in vivo and ex vivo models of I/R [9, 10] , confirming that partial or acute MCU inhibition could be a therapeutic strategy to reduce cell death [27] . Moreover, this cardioprotective effect has been linked to MCU as an ischemic preconditioning (IPC) mediator [6, 28] . The mechanisms implicated in IPC are not fully understood; however, low levels of mCa 2+ -generated ROS are involved as a trigger of IPC by activation of survival kinases [29] . Since a large production of ROS during reperfusion contributes importantly to PTP opening inducing cardiomyocyte death, the controlled ROS production by MCU silencing mimics the IPC cardioprotective effects. Therefore, our findings are in accordance with the observed protection in conditional cardiac-specific MCU −/− mice [14, 15] . In this transgenic model, deletion of MCU in adult cardiomyocytes leads to protection from cell death induced by acute damage such as ischemia-reperfusion injury. However, the results in MCU-knockout constitutive animals are still controversial. For instance, during reperfusion injury, MCU-knockout hearts were similar to control hearts, and CsA did not exert a protective effect. This suggests that Ca 2+ -independent death pathways take place in the absence of MCU and that alternative mechanisms exist for Ca 2+ entry [30] . Of note, inbred MCU-knockout mice are not viable because they are embryonically lethal; only mixedstrain MCU-knockout mice are viable [31] . In addition to this controversy, recent results in MCU overexpressing mice are more resistant to reperfusion injury in part due to an enhanced activity of survival kinases [32] . In addition to defining the contribution of MCU activity in pathologies, the discovery of therapeutic strategies that modulate MCU activity will be extremely important for the future development of putative MCU-targeting therapies. Here, using siRNA or several pharmacological strategies (such as Ru 360 or CsA), we attempted to diminish PTP opening or reduce mCa 2+ overload in order to decrease the likelihood of arrhythmias and postmyocardial infarction cardiac dysfunction [2] . In this regard, in vitro and ex vivo studies of cytosolic Ca 2+ overload and IR injury have shown that CsA is a potent inhibitor of PTP, protecting against reperfusion cardiomyocyte death [8, 33] . Indeed, CsA application in small animal models at the onset of reperfusion has demonstrated a reduction of the myocardial infarct area by ∼45% [34] by suppressing Δ loss, NADH oxidation, Ca 2+ release, and mitochondrial swelling [35] . Accordingly, some clinical trials have been performed to determine its protective effect from reperfusion injury in patients with myocardial infarction [36] . Nevertheless, a recent metaanalysis of randomized controlled trials reveals that CsA could not have protective effects towards reperfusion injury in clinical patients [37] . The cause of these effects is not yet clear, but it could be because CsA is an immunosuppressive agent that has multiple targets such as cyclophilins and calcineurin [38] . Additionally, CsA only increases the threshold of PTP inducers, so it would be desirable to explore another strategy to prevent the formation of PTP and reperfusion injury. On the other hand, the use of Ru 360 as a specific inhibitor of the MCU has been used in intact cardiac cells [7] , isolated hearts [6, 10] , and murine models [9] which provided protection against reperfusion injury, improving mechanical parameters, and decreasing infarct size and intracellular enzymes release [9, 39] . However, their pharmacokinetic parameters, bioavailability, and side effects have not been completely described.
Moreover, these therapeutic strategies that reduce ischemic injury could be beneficial to slow the progression of HF. In this regard, Santulli et al. [40] recently demonstrated that an intracellular Ca 2+ leak could cause mitochondrial Ca 2+ overload and dysfunction in HF murine models. In particular, a sarcoplasmic reticulum Ca 2+ leak can establish a pathological feedback with mitochondria in which mitochondrial dysfunction increases ROS production, which consequently leads to oxidation/nitrosylation of some important sarcoplasmic reticulum channels such as RyR2, enhancing the diastolic Ca 2+ leak and affecting cell contractility. Moreover, we found that selective MCU inhibition has the therapeutic potential to prevent catecholamine-induced toxicity as observed in HF [41] . In this regard, Anderson's group using MCU dominant-negative transgenic mice confirmed our findings of MCU's role on catecholamine response, because their mice were incapable of reaching catecholamine response [14, 27] . These novel data provide experimental rationale to explore the role of MCU during HF development.
At present, knockdown of gene expression by siRNA technologies offers a potent therapeutic approach to specific modulation of gene targeting [42] . siRNA therapeutics is suitable for drug use because it does not require genome integration and can be inexpensive and easily synthesized. Since a rational design of siRNA can specifically inhibit endogenous gene expression, it can modulate any diseaserelated gene expression [43] . Because of their great therapeutic potential, at least 20 siRNA-based drugs have now entered clinical trials in humans [43] . However, siRNA molecules are unstable in the serum and have shown poor cellular uptake and immunogenicity [44] . In this regard, the successful application of siRNA for therapy requires the development of effective drug delivery systems, in particular, nanovectors [45] . Recently, endothelial dysfunction present in HF has been explored as a novel avenue for the delivery of nanovectors, and the resulting endothelial permeability opens the field to nanotechnology-based therapies that could reach the myocardium through dysfunctional permeable endothelium [46] . In a murine model of HF, a passive intracardiac accumulation of high concentrations of nanocarriers occurred after a single application. Compared to the normal heart tissues, the accumulation of nanovectors was 12 times higher in HF animals [47] . This approach should be used as a potential avenue for siRNA-MCU therapy in reperfusion injury or HF, potentially translating towards novel therapies that might improve patient outcomes.
Conclusion
In summary, as the first proof of concept, we have shown that MCU silencing by specific siRNA reduces in vitro H/R injury as seen by cardiomyocyte death abatement. Therefore, this knowledge will allow for the development of a suitable delivery system to test the therapeutic potential of this siRNA in an in vivo model of mitochondrial calcium overload and dysfunction as those present in HF. In this context, the novel MCU druggability should be a fertile area of research in the future.
